Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin pretreatments to enhance MAL-induced PpIX
NCT02372370Phase 1Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Dec 2014
- Primary completion
- Dec 2014
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Phase 1, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Protoporphyrin IX fluorescence at 3 hours. Started Dec 2014; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02372370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372370.